BMC
CRSP icon

Bear Mountain Capital’s CRISPR Therapeutics CRSP Stock Holding History

Bear Mountain Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$303 Hold
6
– – ﹤0.01% 181
2026
Q1 		$346 Hold
6
– – ﹤0.01% 161
2025
Q4 		$325 Hold
6
– – ﹤0.01% 167
2025
Q3 		$434 Buy
+6
New +$344 ﹤0.01% 206

Other funds holding CRSP

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

Bear Mountain Capital's CRSP Position: Q2 2026 in Review

Bear Mountain Capital held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 6 shares worth $303. The position accounts for ﹤0.01% of the portfolio, ranked #181.

Bear Mountain Capital first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $434 in Q3 2025. 159 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bear Mountain Capital held 6 shares of CRISPR Therapeutics worth $303 as of Q2 2026.
  • Bear Mountain Capital left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Bear Mountain Capital's portfolio in Q2 2026, its #181 holding.
  • Bear Mountain Capital first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bear Mountain Capital's CRISPR Therapeutics position peaked at $434 in Q3 2025.
  • 159 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bear Mountain Capital's 13F filing for Q2 2026, filed 20 Jul 2026.